Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Photochemotherapy (0):
Recent article
Photochemotherapy
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was in...
|
PMID: 22057348
PDF is available here.
PDF is available here.